{"id":1359,"date":"2016-01-10T20:53:42","date_gmt":"2016-01-10T20:53:42","guid":{"rendered":"https:\/\/grail.wpengine.com\/?post_type=press-release&p=1359"},"modified":"2021-01-16T00:37:21","modified_gmt":"2021-01-16T00:37:21","slug":"illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/","title":{"rendered":"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening"},"content":{"rendered":"

Significant Development in the War on Cancer<\/p>\n

SAN DIEGO\u2013(BUSINESS WIRE)\u2013Jan. 10, 2016\u2013 Illumina, Inc. (NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood.<\/p>\n

Detecting cancer at the earliest stages dramatically increases long-term survival, hence the successful development of a pan-cancer screening test for asymptomatic individuals would make the first major dent in global cancer mortality.<\/p>\n

GRAIL\u2019s unique structure enables it to take on this grand challenge. GRAIL has been formed as a separate company, majority owned by\u00a0Illumina. GRAIL is initially funded by over\u00a0$100 million\u00a0in Series A financing from\u00a0Illumina\u00a0and\u00a0ARCH Venture Partners, with participating investments from Bezos Expeditions,\u00a0Bill Gates\u00a0and\u00a0Sutter Hill Ventures. GRAIL\u2019s unique relationship with\u00a0Illumina\u00a0provides the ability to economically sequence at the high depths necessary to create a screening test with the required sensitivity and a hoped for level of specificity never before achievable for cancer screening.<\/p>\n

\u201cWe hope today is a turning point in the war on cancer,\u201d said\u00a0Jay Flatley,\u00a0Illumina\u00a0Chief Executive Officer and Chairman of the Board of GRAIL. \u201cBy enabling the early detection of cancer in asymptomatic individuals through a simple blood screen, we aim to massively decrease cancer mortality by detecting the disease at a curable stage.\u201d<\/p>\n

\u201cThe holy grail in oncology has been the search for biomarkers that could reliably signal the presence of cancer at an early stage,\u201d said Dr.\u00a0Richard Klausner, formerly\u00a0Illumina\u00a0Chief Medical Officer and NCI Director, and a Director of GRAIL. \u201cIllumina\u2019s sequencing technology now allows the detection of circulating nucleic acids originating in the cancer cells themselves, a superior approach that provides a direct rather than surrogate measurement.\u201d<\/p>\n

\u201cGRAIL\u2019s rigorous, science-based approach with leading medical and policy advisors worldwide is unprecedented in the fight to defeat cancer,\u201d said\u00a0Robert Nelsen, Managing Director and Co-Founder of\u00a0ARCH Venture Partners\u00a0and a Director of GRAIL.<\/p>\n

GRAIL has secured the counsel of a world-class set of industry and cancer experts for the company\u2019s advisory board, including Dr.\u00a0Richard Klausner; Dr.\u00a0Jose Baselga, Physician In Chief at Memorial Sloan Kettering and President of the\u00a0American Association of Cancer Research; Dr.\u00a0Brian Druker, Director,\u00a0OHSU Knight Cancer Institute;\u00a0Mostafa Ronaghi, Chief Technology Officer at\u00a0Illumina;\u00a0Don Berry, Professor at\u00a0MD Anderson Cancer Center;\u00a0Timothy Church, Professor at the University of\u00a0Minnesota School of Public Health\u00a0and\u00a0Charles Swanton, Group Leader at the\u00a0Francis Crick Institute. The company will initially have a five-member Board of Directors, including\u00a0Jay Flatley,\u00a0William Rastetter\u00a0(Chairman of\u00a0Illumina), Dr.\u00a0Richard Klausner,\u00a0Robert Nelsen, and the CEO. The company is actively recruiting a CEO.<\/p>\n

About\u00a0Illumina<\/b><\/p>\n

Illumina\u00a0is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit\u00a0www.illumina.com<\/a>\u00a0and follow @illumina.<\/p>\n

About GRAIL \u2013\u00a0<\/b>Learn more at Grailbio.com.<\/p>\n

Forward-Looking Statement for\u00a0Illumina<\/b><\/p>\n

This release contains forward looking statements that involve risks and uncertainties, such as Illumina\u2019s expectations for the performance and utility of products to be developed by GRAIL. Important factors that could cause actual results to differ materially from those in any forward-looking statements include challenges inherent in developing, manufacturing, and launching new products and services and the other factors detailed in our filings with the\u00a0Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.<\/p>\n

View source version on businesswire.com:\u00a0<\/span>http:\/\/www.businesswire.com\/news\/home\/20160110005039\/en\/<\/a><\/span><\/p>\n

Source:\u00a0Illumina, Inc.<\/p>\n

 <\/p>\n

\n

Source:\u00a0Read Article on Illumina<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Significant Development in the War on Cancer SAN DIEGO\u2013(BUSINESS WIRE)\u2013Jan. 10, 2016\u2013 Illumina, Inc. (NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood. Detecting cancer at the […]<\/p>\n","protected":false},"featured_media":1303,"parent":0,"menu_order":0,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1359","press-release","type-press-release","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\nIllumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL\" \/>\n<meta property=\"og:description\" content=\"Significant Development in the War on Cancer SAN DIEGO\u2013(BUSINESS WIRE)\u2013Jan. 10, 2016\u2013 Illumina, Inc. (NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood. Detecting cancer at the […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/\" \/>\n<meta property=\"og:site_name\" content=\"GRAIL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/grailbio\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-01-16T00:37:21+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26@2x-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"423\" \/>\n\t<meta property=\"og:image:height\" content=\"172\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@grailbio\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/\",\"url\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/\",\"name\":\"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL\",\"isPartOf\":{\"@id\":\"https:\/\/grail.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg\",\"datePublished\":\"2016-01-10T20:53:42+00:00\",\"dateModified\":\"2021-01-16T00:37:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg\",\"width\":423,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/grail.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/grail.com\/#website\",\"url\":\"https:\/\/grail.com\/\",\"name\":\"GRAIL\",\"description\":\"Detect cancer early, when it can be cured\",\"publisher\":{\"@id\":\"https:\/\/grail.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/grail.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/grail.com\/#organization\",\"name\":\"GRAIL, LLC\",\"url\":\"https:\/\/grail.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"contentUrl\":\"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png\",\"width\":512,\"height\":512,\"caption\":\"GRAIL, LLC\"},\"image\":{\"@id\":\"https:\/\/grail.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/grailbio\/\",\"https:\/\/x.com\/grailbio\",\"https:\/\/www.linkedin.com\/company\/grail-inc.\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/","og_locale":"en_US","og_type":"article","og_title":"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL","og_description":"Significant Development in the War on Cancer SAN DIEGO\u2013(BUSINESS WIRE)\u2013Jan. 10, 2016\u2013 Illumina, Inc. (NASDAQ:ILMN) today announced GRAIL, a new company formed to enable cancer screening from a simple blood test. Powered by Illumina sequencing technology, GRAIL will develop a pan-cancer screening test by directly measuring circulating nucleic acids in blood. Detecting cancer at the […]","og_url":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/","og_site_name":"GRAIL","article_publisher":"https:\/\/www.facebook.com\/grailbio\/","article_modified_time":"2021-01-16T00:37:21+00:00","og_image":[{"width":423,"height":172,"url":"http:\/\/grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26@2x-1.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@grailbio","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/","url":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/","name":"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening - GRAIL","isPartOf":{"@id":"https:\/\/grail.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage"},"image":{"@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage"},"thumbnailUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg","datePublished":"2016-01-10T20:53:42+00:00","dateModified":"2021-01-16T00:37:21+00:00","breadcrumb":{"@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#primaryimage","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2020\/12\/Mask-Group-26%402x-1.jpg","width":423,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/grail.com\/press-releases\/illumina-forms-new-company-to-enable-early-cancer-detection-via-blood-based-screening\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/grail.com\/"},{"@type":"ListItem","position":2,"name":"Illumina Forms New Company to Enable Early Cancer Detection via Blood-Based Screening"}]},{"@type":"WebSite","@id":"https:\/\/grail.com\/#website","url":"https:\/\/grail.com\/","name":"GRAIL","description":"Detect cancer early, when it can be cured","publisher":{"@id":"https:\/\/grail.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/grail.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/grail.com\/#organization","name":"GRAIL, LLC","url":"https:\/\/grail.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/","url":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","contentUrl":"https:\/\/assets.grail.com\/wp-content\/uploads\/2021\/01\/cropped-favicon-G.png","width":512,"height":512,"caption":"GRAIL, LLC"},"image":{"@id":"https:\/\/grail.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/grailbio\/","https:\/\/x.com\/grailbio","https:\/\/www.linkedin.com\/company\/grail-inc.\/"]}]}},"_links":{"self":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/1359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/types\/press-release"}],"version-history":[{"count":0,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/press-release\/1359\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media\/1303"}],"wp:attachment":[{"href":"https:\/\/grail.com\/wp-json\/wp\/v2\/media?parent=1359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}